Rapid Micro Biosystems annual free cash flow
2020
2021
2022
2023
2024
2025
Rapid Micro Biosystems Free Cash Flow (FCF) History (RPID)
Rapid Micro Biosystems reported −$31.9M in free cash flow for fiscal 2025, an increase of $13.6M from the previous fiscal year, with a free cash flow margin of −95.01%.
View full Rapid Micro Biosystems company overviewRapid Micro Biosystems free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$31.9M | $13.6M | — | −95.01% |
| 2024 | 2024-12-31 | −$45.5M | $1.4M | — | −162.27% |
| 2023 | 2023-12-31 | −$46.9M | $18.4M | — | −208.38% |
| 2022 | 2022-12-31 | −$65.3M | −$7.1M | — | −381.06% |
| 2021 | 2021-12-31 | −$58.2M | −$26.5M | — | −250.43% |
| 2020 | 2020-12-31 | −$31.7M | — | — | −197.09% |
Rapid Micro Biosystems quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$12.9M | −$2.9M | — | −160.48% |
| Q1 2026 | 2026-03-31 | −$15.5M | −$6.1M | — | −193.10% |
| Q4 2025 | 2025-12-31 | −$3.3M | $6.7M | — | −29.59% |
| Q3 2025 | 2025-09-30 | −$9.1M | −$301,000 | — | −116.41% |
| Q2 2025 | 2025-06-30 | −$10.1M | $512,000 | — | −138.61% |
| Q1 2025 | 2025-03-31 | −$9.4M | $6.7M | — | −130.24% |
| Q4 2024 | 2024-12-31 | −$10.0M | −$92,000 | — | −121.77% |
| Q3 2024 | 2024-09-30 | −$8.8M | $1.3M | — | −116.03% |
| Q2 2024 | 2024-06-30 | −$10.6M | −$1.2M | — | −159.84% |
| Q1 2024 | 2024-03-31 | −$16.1M | $1.3M | — | −287.11% |
| Q4 2023 | 2023-12-31 | −$9.9M | $2.6M | — | −156.46% |
| Q3 2023 | 2023-09-30 | −$10.2M | $6.5M | — | −165.35% |
| Q2 2023 | 2023-06-30 | −$9.4M | $7.6M | — | −188.02% |
| Q1 2023 | 2023-03-31 | −$17.4M | $1.7M | — | −346.47% |
| Q4 2022 | 2022-12-31 | −$12.5M | $2.4M | — | −285.00% |
| Q3 2022 | 2022-09-30 | −$16.7M | $3.1M | — | −352.23% |
| Q2 2022 | 2022-06-30 | −$17.0M | −$4.9M | — | −439.77% |
| Q1 2022 | 2022-03-31 | −$19.2M | −$7.6M | — | −460.43% |
| Q4 2021 | 2021-12-31 | −$14.9M | −$5.9M | — | −285.20% |
| Q3 2021 | 2021-09-30 | −$19.8M | — | — | −286.53% |
| Q2 2021 | 2021-06-30 | −$12.0M | — | — | −196.53% |
| Q1 2021 | 2021-03-31 | −$11.5M | — | — | −230.49% |
| Q3 2020 | 2020-09-30 | −$9.0M | — | — | −171.36% |
Rapid Micro Biosystems free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$31.7M to −$31.9M, a net decrease of $226,000. Rapid Micro Biosystems's latest reported quarter, Q2 2026, generated −$12.9M in free cash flow, a decrease of $2.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Rapid Micro Biosystems filings at SEC.gov ↗